Document is current

Article History

Accepted: 20 December 2024

First Online: 20 January 2025

Competing interests

: N.N. has received fees as a speaker and/or advisory board member from AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Eli Lilly, Illumina, Incyte, Merck, Merck Sharpe & Dohme, Novartis, Roche, Sanofi and Thermofisher; works in an institution that receives financial support from AstraZeneca, Biocartis, Illumina, Merck, QIAGEN, Roche and Thermofisher; is the President of the International Quality Network for Pathology; and is the past President of the Italian Cancer Society. A.M. has received fees for lectures, presentations, speakers’ bureaus and/or educational events from AstraZeneca, Bristol Myers Squibb, Boehringer, Italfarmaco, Eli Lilly, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, Sanofi and Takeda; and has been an advisory board member for AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme, Pfizer, Roche and Takeda. E.B. works in an institution that receives research grants from AstraZeneca and Roche; has received fees as a speaker and/or for travel from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Novartis, Pfizer and Roche; has received financial support as a speaker from Takeda Oncology; and serves on the Data Safety and Monitoring Board of Merck Sharpe & Dohme for activities outside of the submitted work. F.C. has received fees as an advisory board member and/or for lectures from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Galecto, Illumina, Eli Lilly, Merck Sharpe & Dohme, Mirati, Novocure, Ose Immunotherapeutics, Pfizer, Pharmamar, Roche, Sanofi, Takeda and Thermofisher. A.M.R., V.S., L.L., A.D. and A.D.L. declare no competing interests.